藥品名稱
drug name | 公費Pneumococcal Polysaccharide vaccine,Polyvalent (Pneumovax 23, 紐蒙肺多價性肺炎雙球菌疫苗) 25 mcg/0.5 mL/vial |
| 藥檔狀態 | 停用 （需冷藏） |
成 份
Ingredient | Pneumococcal Polysaccharide vaccine, Polyvalent |
| 單位含量 | 25 mcg/0.5 mL/vial |
| Dosage Forms | PneumovaxR 23 Injection: 25 mcg each of 23 polysaccharide isolates/0.5 mL dose (0.5 mL) (公費71歲以上老人) |
| 外觀描述 | 針劑/肌肉注射 |
| Appearance | |
標 示
outward | |
廠商名稱
Manufacturer | 美商默沙東藥廠股份有限公司台灣分公司 |
製 造 商
Manufacturer | Merck Sharp & Dohme Corp.,United States |
字 號
Product ID | 衛署菌疫輸字第000492號 |
藥理分類
Pharmacologic Category | Biologic and Immunologic Agents/ Immunizations/ Vaccines-Bacteria
Inactivated (Bacterial) |
作用機轉
Mechanism of action | Contains purified capsular polysaccharides of pneumococcal types 1, 2, 3, 4, 5, 8, 9, 12, 14, 17, 19, 20, 22, 23, 26, 34, 43, 51, 56, 57, 67, 70 (American Classification). |
| 用途/適應症 | 肺炎疫苗 |
| Use |
Immunizationagainst pneumococcal disease caused by serotypes included in the vaccine. Routine vaccination is recommended for persons ≧50 years of age and persons ≧2 years in certain situations. All immunocompetent patients ≧65 years of age; patients 2-64 years of age with certain high-risk condition, adults aged 19-64 years of age who smoke cigarettes or have asthma; persons aged 2-64 years with cochlear implants
|
衛福部核准適用症狀
MOHW approved indications |
預防肺炎雙球菌性肺炎及肺炎雙球菌性菌血症。
|
| Dose |
Administration Route: IM, SC
Adults:
Primary vaccination: Adults 19-64 years with specified underlying medical conditions and all patients at 65 years of age without previous PPSV23 vaccination should receive one dose of PPSV23. In patients who are pneumococcal vaccine naive (no previous PCV13 or PPSV23 vaccine), administer a single dose of PCV13 followed by 1 dose of PPSV23 8-weeks later
Revaccination: Adults 19-64 years with functional or anatomic asplenia, or who are immunocompromised: One revaccination dose ?5 years after first dose of PPSV23 and ≧8 weeks after PCV13
Pediatrics:
Immunization: Children ≧2 years: IM, SubQ: 0.5 mL as a single dose
Primary vaccination: Children with specified underlying medical conditions: One dose of PPSV23 should be given at ≧2 years of age. Immunization with PCV13 should be completed prior to PPSV23 as recommended. The minimum interval between the last dose of PCV13 and PPSV23 is 8 weeks
Revaccination: Children with functional or anatomic asplenia, or who are immunocompromised: One revaccination dose ≧5 years after the first dose of PPSV23. Revaccination of immunocompetent individuals is generally not recommended
|
懷孕分級
Pregnancy Risk Factor |
C
C/I:Excretion in breast milk unknown/use caution
|
| 禁忌症 |
1. 不可用於對本疫苗內任何成份過敏者、若因疫苗內的任何成份發生急性過敏反應時必須馬上注射epinephrine(濃度比例1:1000)。
2. 除非是對肺炎雙球菌感染為高危險群者，否則注射本疫苗後不可再追加注射。
|
| Contraindications |
Hypersensitivity to pneumococcal vaccine or any component of the formulation
|
| 常見副作用 | |
| Common adverse drug reactions | |
| Adverse Reactions |
Induration and soreness at injection site, arthralgia, anaphylaxia, erythema, Guillain-Barre syndrome, low-grade fever, rash, paresthesias, myalgia
|
監測
Monitoring |
Monitor for syncope for >15 minutes following vaccination.
|
| 警語與注意事項 | 注射用藥。規格：25ug/0.5ml/vial |
| Warnings & precautions | |
| 針劑溶解條件 |
|
| 針劑稀釋條件 |
|
| 針劑不相容性 |
|
| 針劑施打條件 |
肌肉或皮下注射(最好於上臂三角肌或大腿外側部位)，應避免靜脈注射。(990421仿單資料)
111年度擴大公費實施對象至71歲以上長者。
|
| 針劑保存安定性 |
未開封2-8℃冷藏儲存(勿冷凍)；如發生變質或過期，不可再使用。(990421仿單資料)
|
最近修改日期時間
Updated | 10/6/2022 1:58:17 PM |